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Abstract
Background: Riluzole is a neuroprotective drug used in the treatment of motor neurone disease. Recent evidence
suggests that riluzole can up-regulate the expression and activity of the astrocyte glutamate transporter, GLT-1.
Given that regulation of glutamate transport is predicted to be neuroprotective in Parkinson’s disease, we tested
the effect of riluzole in parkinsonian rats which had received a unilateral 6-hydroxydopamine injection into the
median forebrain bundle.
Results: Rats were treated with intraperitoneal riluzole (4 mg/kg or 8 mg/kg), 1 hour before the lesion then once
daily for seven days. Riluzole produced a modest but significant attenuation of dopamine neurone degeneration,
assessed by suppression of amphetamine-induced rotations, preservation of tyrosine hydroxylase positive neuronal
cell bodies in the substantia nigra pars compacta and attenuation of striatal tyrosine hydroxylase protein loss.
Seven days after 6-hydroxydopamine lesion, reactive astrocytosis was observed in the striatum, as determined by
increases in expression of glial fibrillary acidic protein, however the glutamate transporter, GLT-1, which is also
expressed in astrocytes was not regulated by the lesion.
Conclusions: The results confirm that riluzole is a neuroprotective agent in a rodent model of parkinson’s disease.
Riluzole administration did not regulate GLT-1 levels but significantly reduced GFAP levels, in the lesioned striatum.
Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective
effects of this drug.
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Background
The primary pathological event in Parkinson’sd i s e a s ei s
degeneration of the nigrostriatal dopamine neurons. In
Parkinson’s disease, corticostriatal and subthalamonigral
glutamate systems are hyperactive, and contribute to
symptoms and dopamine neuronal death, through the
process of “excitotoxicity” [1-3]. Reducing glutamate
transmission through activating type III metabotropic
glutamate receptors [2,4], blocking type I metabotropic
glutamate receptors [5], or blocking postsynaptic AMPA
or NMDA receptors [6,7] have been shown to be neuro-
protective and reduce motor symptoms in animal
models of Parkinson’s disease. In general, therefore,
anti-glutamate approaches are attractive and promising
therapeutically, although they have not yet led to effec-
tive clinical drugs.
One potential way of regulating glutamate levels,
which has been largely overlooked in Parkinson’sd i s -
ease, is by modulating astrocytes. Astrocytes express
glutamate transporters which remove glutamate from
the synaptic cleft and thus control the duration and
magnitude of glutamate’s actions [8]. In Parkinson’s dis-
ease astrocytes show features typical of reactive astrocy-
tosis [9]. In animal models of Parkinson’s disease,
astrocytes are also markedly altered: following dopamine
neurone degeneration astrocytes become reactive, as
seen by a sustained and progressive increase in the
levels of the astrocyte cytoskeletal protein, glial fibrillary
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cyte morphology [10-12]. Since reactive astrocytosis is
associated with loss of the protective functions in astro-
cytes [13], suppression of astrocyte reactivity may be
beneficial in disease.
We recently identified the clinically used neuroprotec-
tive compound, riluzole, as a positive modulator of the
major astrocyte glutamate transporter, GLT-1, in vitro
[14]. Riluzole has already been through a number of
clinical trials in Parkinson’s disease patients [15-17]. The
largest clinical study published to date was a double-
blind study with 20 patients with early Parkinson’sd i s -
ease, untreated with L-dopa who received 100 mg rilu-
zole per day for up to one year [17]. Here riluzole did
not produce any significant improvement in disability or
reduce the time before patients commenced dopamine
agonist therapy, however the effects of riluzole on dis-
ease progression were not assessed. We therefore tested
riluzole in the 6-hydroxydopamine (6-OHDA) treated
rat model of Parkinson’s disease to determine whether it
can cause neuroprotection and whether protection was
associated with modulation of GLT-1 expression in
astrocytes.
Results
Due to the functional deficit of dopamine transmission
on the ipsilateral, lesion hemisphere following unilateral
6-OHDA lesion, animals show a high level of ipsiversive
rotation when challenged with amphetamine (Figure
1A). Riluzole produced a significant, dose-dependent
reduction in this effect, indicating functional preserva-
tion of the dopaminergic system. In support of this
behavioural evidence, immunostaining revealed that rilu-
zole (8 mg/kg, but not 4 mg/kg) significantly protected
TH positive cells in the substantia nigra pars compacta
from 6-OHDA induced cell death (Figure 1B, C). In
vehicle treated animals, there were an average of 81 ±
6.6 cells (n = 8) counted on the unlesioned side, com-
pared to 27 ± 2.1 cells on the lesioned side (n = 9). Rilu-
zole (8 mg/kg) reduced the 6-OHDA-induced cell loss
on the ipsilateral side from 66.1 ± 2.6% (n = 8) to 55.8
± 4.5% (n = 8) (p < 0.05). Analysis of Western blots
showed that riluzole (8 mg/kg) was able to partially pre-
serve striatal TH levels from lesion-induced depletion
(Figure 1E-F): after riluzole administration, the amount
of TH remaining on the side ipsilateral to the lesion was
approximately 4 times higher than when vehicle was
administered.
We next examined the astrocyte response to unilateral
6-OHDA lesion at 8 days after lesion, and the effect of
riluzole administration. Immunostaining of sections sug-
gested that 6-OHDA lesion caused no change in the
expression of the glutamate transporter, GLT-1 in the
striatum on the lesioned side (Figure 2A, B), although it
caused a prominent increase in reactive astrocytes, as
determined by GFAP immunostaining (Figure 2C, D).
Western blotting confirmed these observations: there
was no change in the striatal levels of GLT-1 protein
following lesions that produced complete loss of tyro-
sine hydroxylase, and upregulated striatal GFAP (Figure
2E).
Figure 3 shows the quantification of the effect of
lesion and/or riluzole treatment on GFAP and GLT-1.
As shown in Figure 3A, 6-OHDA lesion caused an
increase in GFAP protein on the striatum on the
lesioned side to 166 ± 8% (n = 8, p < 0.01) compared to
the intact side (Figure 3A). In animals treated with rilu-
zole (4 or 8 mg/kg/day), there was still a significant
increase in GFAP levels on the lesioned side compared
to the intact side, however the increase in striatal GFAP
on the side of the lesion was significantly reduced in
animals treated with 4 mg/kg/day riluzole compared to
vehicle treated animals by 31 ± 9% (n = 9, p < 0.05).
Treatment of lesioned animals with 8 mg/kg/day rilu-
zole also suppressed lesion-induced elevation of GFAP
by 17 ± 9%, though this increase was not statistically
significant. In these animals, GLT-1 levels were unaf-
fected by lesion and/or riluzole treatment (Figure 3B).
GLAST levels were unaffected by lesion or by treatment
with riluzole (data not shown).
Discussion
We tested riluzole for its ability to confer neuroprotec-
tion in the 6-hydroxydopamine rat, an animal model of
Parkinson’s disease. Our finding, that riluzole protects
dopamine neurones from cell death confirms and
extends the data reported in rats with a unilateral 6-
OHDA (6 μg) lesion which showed that a single riluzole
injection (8 mg/kg) before lesion, and one twenty-four
hours afterwards suppressed apomorphine or ampheta-
mine-induced rotations and significantly reduced the
loss of dopamine in the striatum [18]. Riluzole has also
consistently been demonstrated to provide neuroprotec-
tion in MPTP-treated mice, when administered before
the lesion [19-21]. In non-human primates riluzole
administration either 1 hour prior to, or one hour after
MPTP administration, followed by additional adminis-
trations also caused neuroprotection [22-25]. Our data
therefore confirms that riluzole is an effective neuropro-
tective agent, at least when administration commences 1
h before the experimental lesion.
Motor symptoms of Parkinson’s Disease appear when
around 60-70% of the nigrostriatal tract has degener-
ated, in this study a partial lesion was used to mimic
early stage Parkinson’s Disease, when neuroprotective
strategies might be employed in the clinic. Such lesions
have been successfully adopted in other studies of this
kind in our lab [26]. Nevertheless, we acknowledge that
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because the protective drug is administered before
lesioning. This pre-lesion administration is not clinically
relevant but helps identify whether particular drug tar-
gets and mechanisms are likely to be effective if appro-
priate timing of administration can be achieved with
better pre-symptomatic diagnosis, and is a protocol
employed in many studies. The currently available ani-
mal models are an acknowledged limitation in the field
[27]. The rapidity of cell death which occurs following
experimental administration of dopamine neurotoxins
means that the true mechanisms underlying dopamine
cell death are still being debated.
The current study reveals a significant, but modest,
neuroprotection when measured by protection of tyro-
sine hydroxylase positive cells, yet a larger reduction in
behavioural rotations. As recently reviewed [27], beha-
vioural responses, including amphetamine-induced rota-
tion readouts obtained from animals bearing a partial
lesion of the type used here can be rather variable.
Thus, although amphetamine induces ipsiversive rota-
tions, this may be seen in as few as half the animals
tested [28], and the degree of rotation does not always
change in direct relation to the degree of cell loss across
a wide range of between 50-90% [29-31]. In our study,
protection from 66 to 56% cell loss is reflected in a
Figure 1 Neuroprotective effects of riluzole (4 or 8 mg/kg) given 1 hour before and for 7 days post-lesion in the 6-OHDA rat model of
PD. A. Effect of riluzole or vehicle on ipsilateral rotations in lesioned rats measured between 25-70 minutes after amphetamine administration. B.
Tyrosine Hydroxylase (TH) immunoreactive neurones in the substantia nigra pars compacta (SNpc), scale bar = 0.5 mm. C shows quantification of
TH positive cells in SNpc on the side ipsilateral to the lesion ± SEM, expressed as a % of the unlesioned, intact side (n = 8 per group), * = p <
0.05, One-Way Anova followed by Bonferroni’s test. D. Sections at the level of the striatum stained for TH immunoreactivity. E. Western blot data
shows loss of TH immunoreactivity on lesioned side which is reduced in animals treated with riluzole (8 mg/kg). F shows these data quantified:
for each animal the TH band intensity is divided by the band density of a housekeeping protein, b-tubulin and expressed as % of the intact side
± SEM (n = 8), * = p < 0.05, unpaired t-test.
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making it a useful, but not sole indicator of the degree
of neuroprotection achieved. However, this result sig-
nifies that even a modest degree of cell protection, as
achieved here, can manifest as functional improvement
in motor behaviour if the resultant level of cell preserva-
tion moves beyond the threshold for symptom
generation.
While efficacious in rodent and primate models, rilu-
zole has not proved clinically useful in patients with
Parkinson’s disease [17]. The apparent discrepancy
between the data sets most likely relates to the doses
used. While it is difficult to accurately scale doses from
humans to lower species, the riluzole doses used in this
study (4 mg/kg or 8 mg/kg), typical of the doses
required to produce positive effects in rodents [25,32],
are five to ten fold higher than the dose of riluzole used
clinically for the treatment of Amyotrophic Lateral
Sclerosis/Motor Neuron Disease (ALS/MND). In ALS/
MND patients, 50 mg twice daily is administered, i.e.
between 1-2 mg/kg. This dose has been evaluated as
providing the best benefit:risk ratio in ALS/MND [33],
though doses of up to 200 mg/day are tolerated [33,34].
Riluzole doses such as those used clinically have never
been reported to be effective in primate models of Par-
kinson’s disease, indeed the primate data suggests that
higher doses of riluzole, between 4-10 mg/kg daily are
required for efficacy [22-25], i.e. equivalent to a dose
range in man between 200 mg/day and 1 g/day. A 100
mg/day dose was shown to be ineffective in a clinical
trial in patients with Parkinson’sd i s e a s e[ 1 7 ] ,n od o s e -
ranging was carried out, and it is unknown whether
higher doses would provide benefit. It is possible, there-
fore, that in patients an efficacious riluzole concentra-
tion may not have been achieved, through concerns
about the adverse effects of higher doses. Though rilu-
zole itself, because of its tolerability in man, may never
be effective in Parkinson’sd i s e a s e ,t h ep r o o fo fc o n c e p t
obtained in rodent and primate studies, including this
one suggests that the drug is targeting a mechanism
which is important in disease progression, thus suggest-
ing routes for future therapies.
Riluzole’s neuroprotective effects are generally
regarded to be caused by its effects on reducing gluta-
mate release in neurones following inhibition of voltage-
gated sodium cation channels [35]. However, sodium
channel blockers such as lamotrigine are ineffective in
animal models of PD [36]. In addition, riluzole has addi-
tional, incompletely-characterised pharmacological
effects which may be independent of effects on the per-
sistent sodium current e.g. [37]. Since we had demon-
strated that riluzole increases levels and activity of the
glutamate transporter GLT-1 in primary cultures of
striatal astrocytes [14], we reasoned that this transporter
may be regulated by riluzole in vivo. However this study
clearly demonstrates that riluzole does not regulate
GLT-1 within one week of this partial 6-OHDA lesion.
Our data shows that, even though striatal astrocytes
become reactive following 6-OHDA lesion there is no
regulation of GLT-1 protein levels. This observation is
Figure 2 Effect of 6-OHDA on neurochemical markers in striatum. Panels A-D are photomicrographs of striatum seven days following 6-
OHDA administration, showing GLT-1 immunostaining in striatum on lesioned (A) and intact (B) side and GFAP immunostaining - green on
lesioned (C) and intact (D) side. Scale bar = 50 μm. E shows Western blots of striatal protein samples taken from 6-OHDA lesioned animals. Blots
from two animals are shown for comparison. Membranes were blotted with antibodies against tyrosine hydroxylase (TH), GLT-1, GLAST, GFAP or
beta-tubulin (btub). Molecular weights (KDa) of protein bands are indicated, the glutamate transporters GLT-1 and GLAST are found as
monomeric (67 KDa) and multimeric (ca. 190 KDa) species.
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reactive astrocytes in vivo in other animal models of
neurodegeneration, for exam p l eat r a n s g e n i cm o d e lo f
motor neurone disease [38]. The underlying mechan-
isms which determine extent of loss of GLT-1 in reac-
tive astrocytes are incompletely understood, but are
likely to relate to the extent of astrocyte activation and
the degree of preservation of the afferent input to astro-
cytes, which support continued GLT-1 expression [39].
In the current study, we find GLT-1 to be neither up-
nor down- regulated following 6-OHDA lesion, here
measured 7 days after initial lesion. This is similar to
the observations by others that there is no change in
GLT-1 mRNA following striatal 6-OHDA lesion of rats
[40] or in MPTP-treated mice [41]. However, there is
some controversy on this issue; a recent well-controlled
study shows that GLT-1 is upregulated after unilateral
6-OHDA lesions (16 μg) in rats 3 weeks and 12 weeks,
but not 5 weeks after lesion [42], and the changes when
present were found bilaterally, i.e. on the lesioned and
unlesioned side, even though GFAP was significantly
increased only in the striatum on the lesioned side.
There are other studies which suggest that glutamate
uptake activity [43] and GLT-1 protein is down-regu-
lated after more substantial 6-OHDA lesions [44], or
after MPTP treatment of mice [10]. We cannot resolve
these apparent discrepancies at this time, though note
there are differences in the lesion protocols: in this
study we chose a partial lesion that resulted in around
60% depletion of striatal TH, nor did we analyse the
striatum at later time points, when later changes may
potentially occur. We note that, in the animals used in
this study, the degree of activation of astrocytes is likely
to be relatively mild compared to studies with a more
complete dopamine neurone lesion.
Following 6-OHDA lesion there was a significant ele-
vation of the astrocyte marker, GFAP, as expected
[10-12]. Increased GFAP is usually interpreted as a mar-
ker of reactive astrogliosis, a phenotypic changes which
include increased GFAP expression and elaboration of
astrocyte processes [45]. Herew es h o wq u a n t i t a t i v e l y
that riluzole has a marked effect on astrocytes in a
model of neurodegeneration, as shown by its ability to
reduce GFAP levels, both in the intact and lesioned
striatum. Other groups have also suggested that riluzole
treatment alters astrocyte morphology and GFAP
expression in MPTP-treated mice [20,46]. It is possible
that the ability of riluzole to suppress reactive astrocyto-
sis may contribute to the neuroprotective effects
observed in this study. As well as glutamate uptake,
astrocytes exert a number of protective effects on neu-
rones, and riluzole-induced reduction in astrocyte reac-
tivity may lead to a suppression of neuroinflammatory
pathways, a reduction in oxidative stress, hypotheses
which can be tested in future studies.
Methods
Male Sprague Dawley rats (B & K or Harlan, U.K.)
weighing 270 - 300 g were used in these studies. Food
and water were provided ad libitum.A n i m a l sw e r e
housed in a temperature- and humidity-controlled
environment with a 12-h light/dark cycle. All procedures
conformed to the U.K. Animals (Scientific Procedures)
Act, 1986 and institutional ethical approval. For unilat-
eral lesions, rats were pre-treated with desipramine (25
mg/kg i.p.) and pargyline (5 mg/kg i.p.) 30 minutes
prior to induction of isoflurane anaesthesia. In fully
anesthetised animals, 8 μg 6-OHDA (dissolved in 2.5 μl
of 0.02% ascorbic acid/0.9% saline) was infused into the
Figure 3 Effect of riluzole on astrocyte protein expression in
the striata of animals bearing a 6-OHDA lesion. Western blots
were quantified, and band density of GFAP and GLT-1 calculated
relative to the housekeeping protein, b-tubulin. Graphs show the
relative expression levels of each of these proteins on the intact
side (open bars) and lesioned side (filled bars) in 6-OHDA lesioned
animals ± SEM (n = 8-9) ** = p < 0.01 compared to vehicle-treated
intact side, † = p < 0.05 compared to vehicle-treated lesioned side.
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min via an infusion pump. The stereotaxic coordinates
used were: AP: -2.8, ML: +2.0, DV: -9.0 (from skull sur-
face) relative to bregma with the incisor bar set at -3.3
mm [4]. Animals were treated with riluzole (4 or 8 mg/
kg/kg, i.p., Tocris, Avonmouth UK) or PBS vehicle one
hour prior to the first 6-OHDA injection and daily for
7 days thereafter.
We chose our lowest dose on the basis of previous
work in rodent stroke models which used 4 mg/kg to
see protective effects [32], and the highest dose on the
basis of doses which have already been suggested to
show protection in PD models, for example a recent pri-
mate studies which used 10 mg/kg riluzole to produce
protective effects [25].
The extent of motor impairment in animals was
assessed using amphetamine-induced rotational beha-
viour testing at 7 days post-lesion. Animals were har-
nessed in jackets tethered to an automated rotometer,
placed in 40 cm diameter bowls and recorded for a 10
min baseline period before injection of d-amphetamine
(5 mg/kg i.p.). Full 360° ipsiversive rotations were
recorded in 5-min intervals for up to 90 min post-injec-
tion for subsequent assessment by observers blinded to
treatment.
For immunostaining, on the final day of dosing (day
8), animals were terminally anaesthetised using pento-
barbital (100 mg/kg) then trans-cardially perfused with
0.1 M PBS, followed by 4% paraformaldehyde in 0.1 M
PBS. The brains were removed and stored in PFA at 4°
C. Coronal sections (15 μm) were cut on a vibrating
microtome and free floating sections were incubated
with blocking buffer (1% normal goat serum in 0.1 M
PBS) then overnight with rabbit anti -tyrosine hydroxy-
lase (TH) antibody (1:1250; Chemicon), rabbit anti-glial
fibrillary acidic protein (GFAP) antibody (1:1000, Dako),
rabbit anti-GLT-1 (1:4000, gift of D. Pow, Brisbane).
After three PBS washes, sections were incubated for 1 h
with secondary antibody (biotinylated goat anti-rabbit
1:200; Sigma) then incubated for 30 min with an ABC
kit (Vector Labs) and the signal developed in 10% dia-
minobenzidine tetrahydrochloride (DAB) in Tris-buf-
fered saline for 10 min. In some experiments, the
fluorescent secondary antibody, anti-rabbit Alexa 488
(1:1000) (Invitrogen, Paisley, UK) was used. Immunos-
tained sections were viewed on a Zeiss apotome micro-
scope and recorded using Axiovision LE software (Carl
Zeiss Ltd., Hertfordshire, UK) at 50× magnification. To
obtain cell counts in the substantia nigra pars compacta
(SNpc), only viable TH-positive cells (i.e. intact round
cells displaying a clear nucleus and cytoplasm) were
counted in each hemisphere using image analysis soft-
ware (Image J, NIH, Bethesda, MD). Previous studies
have shown that data obtained using full stereological
counting and manual counting of TH-positive cells in
t h eS N p ci nt h e6 - O H D Ar a tm o d e la r ei n d i s t i n g u i s h -
able [47], so manual counting was adopted here. For
each animal, the numbers of cells in three adjacent sec-
tions of SNpc was counted in both ipsilateral and con-
tralateral hemispheres at three different rostrocaudal
level (-4.8, -5.3, and -5.8 mm AP from Bregma), and
averaged to give a mean cell count per section for the
ipsilateral and contralateral sides. TH-positive cell
counts in the 6-OHDA lesioned side, expressed as % of
the contralateral, intact hemisphere, were compared
between treatment groups using a One-way ANOVA
and Bonferroni post-hoc test.
For Western blotting, on the final day of dosing rats
were killed by terminal anaesthesia, and the brains
rapidly dissected and regions frozen on dry ice. Western
blotting of samples was carried out as described else-
where [48]. Membranes were incubated with the follow-
ing antibodies: rabbit anti GFAP (1:1000, Dako), rabbit
anti-GLT-1 (1:4000, gift of D. Pow, Brisbane) or mouse
anti-beta tubulin (1:400, Sigma-Aldrich). Detection was
carried out using a horseradish peroxidase-conjugated
goat anti-rabbit or anti-mouse IgG, as appropriate
(1:1000, Sigma) using ECL Western blotting detection
reagents and film detection (GE Healthcare). Bands
were analysed using ImageJ (NIH, Bethesda, MD). GLT-
1 quantification was obtained by quantifying both the
lower (monomeric) and the high molecular mass (multi-
meric) bands, as described previously [49].
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